Core Insights - The company is well-positioned in the market with growing demand for its services and a diversified business model across various healthcare segments [3] Company Operations - The organization has recently welcomed back Debbie Osteen as CEO, whose industry experience and operational expertise have revitalized the employee base [4] - Todd Young, the new CFO, has been with the company for four months and is adapting to the services side of healthcare after a background in product [2] Business Segments - The company operates in multiple areas including acute inpatient, specialty inpatient, residential, and outpatient services, particularly focusing on opioid replacement therapy known as CTC [3]

Acadia Healthcare Company Conference Call Summary Company Overview - **Company**: Acadia Healthcare Company (NasdaqGS: ACHC) - **Date of Conference**: March 09, 2026 - **Speaker**: Todd Young, CFO Key Points Company Positioning and Market Demand - Acadia Healthcare is well-positioned in the market with growing demand for its services across various segments, including acute inpatient, specialty inpatient, residential, and outpatient services, particularly opioid replacement therapy (CTC) [2][3] - The return of Debra K. Osteen as CEO has revitalized the organization, creating excitement among employees and enhancing operational capabilities [3] Growth Opportunities - The company has expanded its facilities significantly over the past few years, which provides a solid foundation for growth without requiring substantial additional capital [3][4] - There is a focus on improving execution and ensuring the right leadership is in place to drive growth and fill hospitals effectively [4][5] Challenges and Underperformance - Some new facilities have underperformed due to overly optimistic initial expectations and delays in licensure processes, which affected staffing and operational costs [16][17] - The company is concentrating on improving the performance of underperforming facilities rather than closing them, with a focus on maximizing occupancy [20][21] Financial Guidance and EBITDA - The company has guided for an EBITDA of approximately $600 million, with an additional $200 million in embedded earnings expected [33] - The focus is on achieving operational efficiency and improving the performance of facilities to meet financial targets [35] Malpractice and Legal Challenges - The cost of malpractice claims has increased significantly, with a 186% rise in claims last year, leading to a substantial increase in reserves [42][43] - The company is actively monitoring claims and has increased its reserves to $155 million, reflecting a proactive approach to managing legal risks [44] Medicaid and Payer Relationships - Managed Medicaid has been a pressure point, but the company is focused on advocacy and documentation to navigate payer negotiations effectively [49] - The company has seen an increase in bad debt but expects stability in 2026, with ongoing efforts to improve payer relationships [48][49] Capital Expenditure and Share Buyback - Acadia is reducing its capital expenditures significantly in 2026, focusing on operational efficiency rather than new facility builds [70][72] - The company is prioritizing debt repayment over share buybacks, with a leverage ratio of approximately 4x [70] Outpatient Strategy - The company emphasizes a continuum of care, integrating outpatient services as a step-down from acute care, particularly in its opioid replacement therapy business [51] Future Outlook - Acadia plans to continue expanding its existing facilities rather than opening new ones, with a target of adding 400-600 beds across its operations [31][32] - The company is focused on operational excellence and maximizing the utilization of its current facilities to drive profitability [38] Additional Insights - The company is actively seeking to backfill lost patient populations due to changes in Medicaid policies, particularly in New York [22][24] - Acadia is committed to improving its operational structure and reducing unnecessary meetings to enhance decision-making efficiency [12][14]

On February 17, 2026, Canyon Capital Advisors reported in a Securities and Exchange Commission (SEC) filing that it sold all 521,774 shares of Acadia Healthcare (NASDAQ:ACHC) in the fourth quarter. What happened According to a filing with the Securities and Exchange Commission dated February 17, 2026, Canyon Capital Advisors fully exited its position in Acadia Healthcare by selling 521,774 shares. The quarter-end position value decreased by approximately $12.92 million as a result. What else to know T ...

Volume: ramping the 2,500 beds added over the last three years and bringing new beds online more efficiently.Osteen said her focus in returning to the CEO role is to build a strong company centered on excellence in patient care while also creating shareholder value. She laid out four key areas of focus:She also pointed to payer and geographic diversification, noting that 57% of payers are Medicaid across service lines and that no single state represents more than 15% of revenue .Osteen described Acadia as a ...

PresentationJohn RansomRaymond James & Associates, Inc., Research Division [ Good morning ], everybody. John Ransom. Welcome to our 47th IIC. I've been told I have to say that every time. So you'll get used to hearing that. In a very well-timed sequence of events, we have the returning CEO of ACHC, who made a lot of news last week. You can pull up the chart and see how the stock traded. This is Debbie's second time to have to come back to clean up a mess that she didn't make. So she knows how to do it. And ...

Acadia Healthcare Company (NasdaqGS:ACHC) FY Conference Summary Company Overview - Acadia Healthcare is a leading provider in the behavioral health sector, with a revenue of **$3.3 billion** for the full year of **2025** and treating **84,000 patients daily** [6][15] - The company operates **277 facilities** across **40 states**, with a diverse service offering including acute care, specialty services, residential treatment centers, and outpatient clinics [6][7] Core Business Insights - **Service Line Revenue**: - Acute care is the largest service line, contributing **70%** of revenue - Specialty services and outpatient clinics each account for **17%** of revenue - **57%** of payers are Medicaid [7][8] - **Patient Care Focus**: - Emphasis on improving patient care outcomes and safety, with ongoing investments in technology and staff training [8][9][12] - The company has added **2,500 new beds** over the last three years, with an additional **400-600 beds** expected in **2026** [10][18] Financial Performance and Projections - **Q4 Performance**: - Achieved **3.1% same-store volume growth**, an acceleration from Q3 [16] - Revenue guidance for **2026** is projected between **$3.37 billion** and **$3.45 billion**, with adjusted EBITDA between **$575 million** and **$610 million** [16][18] - **Challenges**: - Anticipated **350 basis point headwind** to same-store growth due to New York Medicaid restrictions [17] - A significant reduction in capital expenditures (CapEx) of over **$300 million** from **2025 to 2026** as new facilities are finalized [18] Operational Strategy - **Operational Excellence**: - Focus on enhancing payer relationships and ensuring appropriate reimbursement [11] - Emphasis on capital discipline and expense management for sustainable growth [11][12] - **Workforce Development**: - Aiming to recruit, retain, and train qualified staff, with improved retention rates noted [12][13] Legal and Compliance Considerations - **Malpractice Expenses**: - **$115 million** in malpractice expenses for **2025**, projected to decrease to **$100 million-$110 million** in **2026** [33] - Increased insurance costs and higher self-retention levels noted, with a focus on monitoring claims and settlements [34] Quality and Safety Initiatives - **Quality Metrics**: - Implementation of real-time tracking for incidents and outcomes at facilities to enhance patient safety [35][36] - Continuous investment in staff training to ensure high-quality patient care [38] Market Dynamics - **Demand for Services**: - Strong ongoing demand for behavioral health services, with a noted shortage of resources to meet patient needs [20] - **Outpatient Services**: - The company is focusing on expanding outpatient services, which are seen as essential for patient progression after stabilization [52][57] Conclusion - Acadia Healthcare is positioned for growth with a strong focus on operational execution, patient care, and strategic investments in facilities and workforce. The company faces challenges from regulatory changes and market dynamics but remains committed to enhancing shareholder value through improved patient outcomes and operational efficiency.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35331 ACADIA HEALTHCARE COMPANY, INC. (Exact name of registrant as specified in its charter) Delaware 45-2492228 (State or other jur ...

Core Viewpoint - Acadia Healthcare Company, Inc. is a prominent provider in the inpatient behavioral health care sector, focusing on delivering quality services while aiming for financial growth [1] Financial Performance - In Q4 2025, Acadia reported adjusted earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.03 per share, resulting in an earnings surprise of over 164% [2][6] - Despite the earnings surprise, the company's profit declined by 89% year-over-year, while total revenues reached $821.5 million, reflecting a 6.1% increase compared to the previous year, surpassing the expected $799 million [3][6] - The revenue growth was attributed to a 3.1% increase in patient days and a 2.5% rise in admissions, leading to a 4.4% increase in same-facility revenues [3] Future Projections - Acadia anticipates revenues for 2026 to be between $3.37 billion and $3.45 billion, with adjusted EBITDA projected to range from $575 million to $610 million [4][6] - The company's projections indicate a strategic focus on service expansion and operational efficiency optimization, despite challenges such as a decrease in average length of stay and rising expenses [4] Stock Performance - Currently, ACHC's stock price is $21.48, reflecting a 3.09% increase, with fluctuations between a low of $20.88 and a high of $22.27 during the trading day [5] - Over the past year, the stock has seen a high of $42.85 and a low of $11.43, with a market capitalization of approximately $1.94 billion [5]

Core Viewpoint - Acadia Healthcare is a leading provider in the inpatient behavioral health care sector, recognized for its strong performance and unique market position [1]. Financial Performance - In the fourth quarter, Acadia reported adjusted earnings of $0.07 per share, exceeding the Zacks Consensus Estimate of $0.03, resulting in an earnings surprise of +164.15%. This is a decrease from $0.64 per share in the same quarter last year, but the company has consistently surpassed consensus EPS estimates over the last four quarters [3]. - Total revenues for the quarter reached $821.5 million, surpassing the expected $799 million, marking a 6.1% year-over-year increase driven by higher patient days and admissions, as well as increased revenues per patient day. However, this growth was partially offset by a shorter average length of stay and increased expenses [4]. Future Outlook - Acadia anticipates 2026 revenues to be between $3.37 billion and $3.45 billion, with adjusted EBITDA projected to range from $575 million to $610 million [5][6]. - Following the announcement of its fourth-quarter and full-year 2025 results, Acadia's stock experienced a 23% surge, benefiting from a broader market upswing, with a market capitalization of approximately $2 billion [5]. Analyst Ratings - Raymond James maintained an "Outperform" rating for Acadia Healthcare, indicating confidence in the company's future performance despite a recommendation to "hold" the stock [2][6].

Group 1 - The article promotes a weekly newsletter focused on stocks in the biotech, pharma, and healthcare industries, highlighting key trends and catalysts that influence market valuations [1] - Edmund Ingham, a biotech consultant with over 5 years of experience, leads the Haggerston BioHealth investing group, which caters to both novice and experienced investors [1] - The investing group provides insights on product sales forecasts, integrated financial statements, discounted cash flow analysis, and market-specific analyses for major pharmaceutical companies [1]